(MDT) Medtronic - Ratings and Ratios
Pacemaker, Defibrillator, Stent, Pump, Monitor
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.12% |
| Yield on Cost 5y | 2.81% |
| Yield CAGR 5y | 3.46% |
| Payout Consistency | 97.7% |
| Payout Ratio | 50.3% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 21.0% |
| Value at Risk 5%th | 32.6% |
| Relative Tail Risk | -5.84% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.65 |
| Alpha | 8.32 |
| CAGR/Max DD | 0.48 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.516 |
| Beta | 0.421 |
| Beta Downside | 0.485 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.77% |
| Mean DD | 6.21% |
| Median DD | 5.74% |
Description: MDT Medtronic December 02, 2025
Medtronic plc (NYSE:MDT) designs, manufactures, and markets a broad range of device-based therapies across five primary segments: Cardiovascular (pacemakers, defibrillators, ablation tools, remote monitoring), Neuroscience (spinal-cord stimulators, brain-modulation systems, drug-infusion implants), Medical Surgical (AI-enhanced video analytics, robotic platforms, stapling and sealing instruments), Diabetes (insulin pumps, CGM sensors, smart pens), and a suite of ancillary products for a wide array of specialists from cardiologists to ENT surgeons. The company operates globally, with a strong footprint in the United States, Ireland, and other international markets.
Key data points to watch: FY 2023 revenue reached roughly $30 billion, with an operating margin near 28%; the Cardiovascular and Diabetes units together contributed over 55% of total sales, reflecting the aging-population tailwinds and rising prevalence of chronic disease. A notable sector driver is the accelerating adoption of remote patient monitoring, which has boosted recurring-revenue streams and improved reimbursement rates under Medicare’s Chronic Care Management program. Additionally, Medtronic’s exposure to the “value-based care” shift means that procedural volume growth may be tempered by bundled-payment models, making cost-efficiency initiatives a critical performance lever.
For a deeper dive into MDT’s valuation metrics, competitive positioning, and scenario analysis, you might explore the detailed research available on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 4.76b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.41 > 1.0 |
| NWC/Revenue: 40.45% < 20% (prev 31.04%; Δ 9.41% < -1%) |
| CFO/TA 0.08 > 3% & CFO 7.11b > Net Income 4.76b |
| Net Debt (27.82b) to EBITDA (9.27b): 3.00 < 3 |
| Current Ratio: 2.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.29b) vs 12m ago 0.05% < -2% |
| Gross Margin: 62.27% > 18% (prev 0.65%; Δ 6162 % > 0.5%) |
| Asset Turnover: 38.32% > 50% (prev 36.65%; Δ 1.68% > 0%) |
| Interest Coverage Ratio: 9.03 > 6 (EBITDA TTM 9.27b / Interest Expense TTM 710.0m) |
Altman Z'' (< 1.1 .. > 2.6) 3.32
| A: 0.15 (Total Current Assets 24.00b - Total Current Liabilities 9.94b) / Total Assets 91.35b |
| B: 0.35 (Retained Earnings 32.07b / Total Assets 91.35b) |
| C: 0.07 (EBIT TTM 6.41b / Avg Total Assets 90.69b) |
| D: 0.65 (Book Value of Equity 27.80b / Total Liabilities 42.49b) |
| Altman-Z'' Score: 3.32 = A |
ValueRay F-Score (Strict, 0-100) 65.50
| 1. Piotroski: 6.0pt |
| 2. FCF Yield: 3.36% |
| 3. FCF Margin: 14.98% |
| 4. Debt/Equity: 0.60 |
| 5. Debt/Ebitda: 3.00 |
| 6. ROIC - WACC: 1.06% |
| 7. RoE: 9.83% |
| 8. Revenue Trend: 76.34% |
| 9. EPS Trend: 12.99% |
What is the price of MDT shares?
Over the past week, the price has changed by +1.57%, over one month by +3.40%, over three months by +5.42% and over the past year by +17.06%.
Is MDT a buy, sell or hold?
- Strong Buy: 12
- Buy: 5
- Hold: 13
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the MDT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 110.9 | 10.5% |
| Analysts Target Price | 110.9 | 10.5% |
| ValueRay Target Price | 108.3 | 8% |
MDT Fundamental Data Overview January 17, 2026
P/E Forward = 16.2866
P/S = 3.6532
P/B = 2.6019
P/EG = 3.4816
Revenue TTM = 34.76b USD
EBIT TTM = 6.41b USD
EBITDA TTM = 9.27b USD
Long Term Debt = 27.62b USD (from longTermDebt, last quarter)
Short Term Debt = 1.42b USD (from shortTermDebt, last quarter)
Debt = 29.10b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 27.82b USD (from netDebt column, last quarter)
Enterprise Value = 154.80b USD (126.98b + Debt 29.10b - CCE 1.28b)
Interest Coverage Ratio = 9.03 (Ebit TTM 6.41b / Interest Expense TTM 710.0m)
EV/FCF = 29.73x (Enterprise Value 154.80b / FCF TTM 5.21b)
FCF Yield = 3.36% (FCF TTM 5.21b / Enterprise Value 154.80b)
FCF Margin = 14.98% (FCF TTM 5.21b / Revenue TTM 34.76b)
Net Margin = 13.71% (Net Income TTM 4.76b / Revenue TTM 34.76b)
Gross Margin = 62.27% ((Revenue TTM 34.76b - Cost of Revenue TTM 13.11b) / Revenue TTM)
Gross Margin QoQ = 60.32% (prev 57.66%)
Tobins Q-Ratio = 1.69 (Enterprise Value 154.80b / Total Assets 91.35b)
Interest Expense / Debt = 0.62% (Interest Expense 181.0m / Debt 29.10b)
Taxrate = 13.47% (215.0m / 1.60b)
NOPAT = 5.54b (EBIT 6.41b * (1 - 13.47%))
Current Ratio = 2.42 (Total Current Assets 24.00b / Total Current Liabilities 9.94b)
Debt / Equity = 0.60 (Debt 29.10b / totalStockholderEquity, last quarter 48.65b)
Debt / EBITDA = 3.00 (Net Debt 27.82b / EBITDA 9.27b)
Debt / FCF = 5.34 (Net Debt 27.82b / FCF TTM 5.21b)
Total Stockholder Equity = 48.49b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.25% (Net Income 4.76b / Total Assets 91.35b)
RoE = 9.83% (Net Income TTM 4.76b / Total Stockholder Equity 48.49b)
RoCE = 8.42% (EBIT 6.41b / Capital Employed (Equity 48.49b + L.T.Debt 27.62b))
RoIC = 7.23% (NOPAT 5.54b / Invested Capital 76.64b)
WACC = 6.18% (E(126.98b)/V(156.08b) * Re(7.47%) + D(29.10b)/V(156.08b) * Rd(0.62%) * (1-Tc(0.13)))
Discount Rate = 7.47% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -1.68%
[DCF Debug] Terminal Value 85.36% ; FCFF base≈5.32b ; Y1≈5.41b ; Y5≈5.92b
Fair Price DCF = 104.1 (EV 161.30b - Net Debt 27.82b = Equity 133.49b / Shares 1.28b; r=6.18% [WACC]; 5y FCF grow 1.39% → 2.90% )
EPS Correlation: 12.99 | EPS CAGR: -0.20% | SUE: 2.62 | # QB: 4
Revenue Correlation: 76.34 | Revenue CAGR: 3.90% | SUE: 1.26 | # QB: 2
EPS current Year (2026-04-30): EPS=5.65 | Chg30d=+0.001 | Revisions Net=-2 | Growth EPS=+3.0% | Growth Revenue=+7.5%
EPS next Year (2027-04-30): EPS=6.11 | Chg30d=-0.001 | Revisions Net=-1 | Growth EPS=+8.1% | Growth Revenue=+5.7%
Additional Sources for MDT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle